Vaxcyte, Inc. (PCVX)
66.23
+2.55
(+4.00%)
USD |
NASDAQ |
Oct 20, 16:00
65.90
-0.33
(-0.50%)
After-Hours: 07:08
Vaxcyte Research and Development Expense (TTM) : 1.033B for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.033B |
| March 31, 2026 | 958.95M |
| December 31, 2025 | 794.31M |
| September 30, 2025 | 685.86M |
| June 30, 2025 | 592.86M |
| March 31, 2025 | 530.19M |
| December 31, 2024 | 476.64M |
| September 30, 2024 | 447.18M |
| June 30, 2024 | 427.66M |
| March 31, 2024 | 368.85M |
| December 31, 2023 | 332.34M |
| September 30, 2023 | 279.82M |
| June 30, 2023 | 230.08M |
| March 31, 2023 | 195.85M |
| Date | Value |
|---|---|
| December 31, 2022 | 169.45M |
| September 30, 2022 | 140.90M |
| June 30, 2022 | 113.65M |
| March 31, 2022 | 92.83M |
| December 31, 2021 | 78.41M |
| September 30, 2021 | 70.00M |
| June 30, 2021 | 65.98M |
| March 31, 2021 | 66.51M |
| December 31, 2020 | 73.56M |
| September 30, 2020 | 72.28M |
| June 30, 2020 | 65.50M |
| March 31, 2020 | 57.30M |
| December 31, 2019 | 45.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Moderna, Inc. | 2.635B |
| Vir Biotechnology, Inc. | 471.79M |
| Revolution Medicines, Inc. | 1.287B |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |